To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC44535 | PF-05221304(Clesacostat) Featured |
PF-05221304 is an orally bioavailable, liver-directed and dual ACC1 (and ACC2) inhibitor with IC50s of 7.5 nM for rat ACC1, 8.2 nM for rat ACC2, 12.4 nM for human ACC1 and 8.7 nM for human ACC2. PF-05221304 is a substrate for organic anion transport polyp
More description
|
|
| DC34338 | Pyrintegrin Featured |
Pyrintegrin is a cell-permeable promoter of the adhesion of individually dissociated hESCs on matrigel- or laminin-, but not gelatin-coated surfaces, substantially reducing trypsinization-induced apoptosis.
More description
|
|
| DC28735 | PK150 Featured |
PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus
More description
|
|
| DC10289 | PE859 Featured |
PE859 is a potent inhibitor of both tau and Aβ aggregation with IC50 values of 0.66 and 1.2 μM, respectively.
More description
|
|
| DC7223 | Palomid 529 (P529) Featured |
Palomid 529 (P529) is a novel potent inhibitor of both the mTORC1 and mTORC2 complexes with a GI50 of <35 μM in the NCI-60 cell lines panel; reduces phosphorylation of pAktS473, pGSK3βS9, and pS6 but no effect observed on pMAPK or pAktT308.
More description
|
|
| DC10109 | Q203 Featured |
Q203 is a promising new clinical candidate for the treatment of tuberculosis.
More description
|
|
| DC8190 | Ravidasvir hydrochloride (PPI-668) Featured |
Ravidasvir(PPI-668) is a NS5A Inhibitor.
More description
|
|
| DC10878 | Raphin1 Featured |
Raphin1 is an orally available selective phosphatase inhibitor improves proteostasis and
diminishes deficits in a mouse model of Huntington’s disease.
More description
|
|
| DC1048 | Rapamycin (Sirolimus) Featured |
Rapamycin (Sirolimus, AY-22989, WY-090217) is a specific mTOR inhibitor with IC50 of ~0.1 nM. -
More description
|
|
| DCAPI1391 | Ranolazine (Ranexa) Featured |
Ranolazine (Ranexa)
More description
|
|
| DC8940 | Raltitrexed Featured |
Raltitrexed(ZD1694), an inhibitor of thymidylate synthase, is an antimetabolite drug used in cancer chemotherapy.
More description
|
|
| DCAPI1581 | Raltegravir Featured |
Raltegravir Salt is a potent human immunodeficiency virus (HIV) integrase inhibitor and a novel anti-AIDS drug.
More description
|
|
| DC10899 | Ralinepag Featured |
Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.
More description
|
|
| DC9987 | RAF709 Featured |
RAF709 is a novel Raf kinase inhibitor extracted from patent WO2014151616A1, compound example 131, has an IC50 of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
More description
|
|
| DC5049 | RAF265 (CHIR-265) Featured |
RAF265 (CHIR-265) is a highly selective B-Raf and VEGFR2 inhibitor with IC50 of 3-60 nM and EC50 of 30 nM, including B-Raf, C-Raf and mutant B-Raf.
More description
|
|
| DC8011 | Radotinib (IY-5511) Featured |
Radotinib(IY-5511) is a novel and selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM for wild-type BCR-ABL1 kinase.
More description
|
|
| DC10578 | rac BHFF Featured |
Rac BHFF is a potent and selective GABAB receptor positive allosteric modulator that increases the efficacy and potency of GABA ( > 149% and > 15-fold respectively). Orally active and exhibits anxiolytic activity in vivo.
More description
|
|
| DC9103 | Rebeprazole sodium |
Rabeprazole sodium(LY307640 sodium) is an antiulcer drug in the class of proton pump inhibitors.
More description
|
|
| DC1013 | R788 disodium (Fostamatinib) Featured |
R935788 (Fostamatinib disodium, R788) is a Syk inhibitor with IC50 of 41 nM.
More description
|
|
| DC9841 | Fostamatinib(R788) Featured |
R788 (Fostamatinib), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.
More description
|
|
| DC7258 | Bemcentinib(R428,BGB324) Featured |
R428 is a potent and selective small-molecule inhibitor(IC50=14 nM), blocks the activities of Axl.
More description
|
|
| DC8733 | R406 Featured |
R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3.
More description
|
|
| DC1014 | R406 free base Featured |
R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3.
More description
|
|
| DC7037 | R306465(JNJ-16241199) Featured |
R306465, also known as JNJ-16241199, is a novel hydroxamate-based histone deacetylase (HDAC) inhibitor with broad-spectrum antitumour activity against solid and haematological malignancies in preclinical models.
More description
|
|
| DC10692 | R162 Featured |
R162 is an inhibitor of GDH activity and represses glioma cell growth.
More description
|
|
| DC7206 | R1530 Featured |
R1530 is the multikinase inhibitor with potential antiangiogenesis and antineoplastic activities.
More description
|
|
| DC8657 | R112 Featured |
R112 is an ATP-competitive inhibitor of Syk kinase with a Ki of 96 nM. R112 inhibits Syk kinase activity with an IC50 of 226 nM.
More description
|
|
| DC5197 | Quizartinib (AC220) Featured |
Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 1/2.
More description
|
|
| DC7176 | Quisinostat (JNJ-26481585) 2HCl Featured |
Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11.
More description
|
|
| DC23125 | Pyrotinib maleate Featured |
Pyrotinib maleate (SHR-1258 maleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50 of 13/38 nM, respectively.
More description
|
|